PatientGPS™ – Fluid Biomarker Testing for Early Alzheimer’s Disease
The advent of disease-modifying therapies (DMTs) has significantly altered the treatment of Alzheimer’s disease (AD), making timely and accurate diagnosis essential for optimal management. Detecting AD pathology with imaging and fluid biomarkers is critical for identifying patients eligible for these newer therapies. As the fluid biomarker landscape evolves to include blood-based biomarkers alongside cerebrospinal fluid (CSF) testing, clinicians face challenges in integrating these tools into clinical practice